Novel diagnostic and prognostic biomarkers in biliary tract cancer

Expert Opinion on Medical Diagnostics

Volumn 7, Issue 5, 2013, Pages 487-499

  Skipworth, James R A ^a   Timms, John F ^a   Pereira, Stephen P ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biliary tract cancer; Biomarkers; Cholangiocarcinoma; Diagnosis; Gallbladder cancer; Prognosis

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA2 GLYCOPROTEIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BILIRUBIN; BINDING PROTEIN; BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; ELASTASE; FIBRONECTIN; GALECTIN 3; INTERLEUKIN 6; MUCIN 5AC; PHOSPHATIDYLINOSITOL; PYRUVATE KINASE; SECRETED FRIZZLED RELATED PROTEIN 1; SOMATOMEDIN C; TYROSINE 3 MONOOXYGENASE; VASCULOTROPIN; TUMOR MARKER;

ALGORITHM; ARTICLE; BILIARY TRACT CANCER; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CANCER PROGNOSIS; CAPILLARY ELECTROPHORESIS; CAPSULE ENDOSCOPY; CHOLANGITIS; CHOLESTASIS; CIRCULATING TUMOR CELL; CLINICAL EVALUATION; CLONAL EVOLUTION; COLORECTAL CANCER; CYTOPATHOLOGY; CYTOSKELETON; DIAGNOSTIC ACCURACY; DIGESTIVE SYSTEM CANCER; DNA REPLICATION; ENDOSCOPY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE SEQUENCE; IMAGE ANALYSIS; LUNG SMALL CELL CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIMARY BILIARY CIRRHOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; SEROTONIN METABOLISM; STOMACH JUICE; URINALYSIS; BILIARY TRACT NEOPLASMS; HUMAN; METABOLISM; PROGNOSIS;

BILIARY TRACT NEOPLASMS; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883154974     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2013.826646     Document Type: Article

References (114)

1. West J, Wood H, Logan RF, et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer 2006;94:1751-8
2. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353-7
3. Taylor-Robinson SD, Toledano MB, Arora S, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001;48:816-20
4. Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008;248:84-96
5. Khan SA, Miras A, Pelling M, et al. Cholangiocarcinoma and its management. Gut 2007;56:1755-6
6. Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: Consensus document. Gut 2002;51(Suppl 6):VI1-9
7. Saengsawang P, Promthet S, Bradshaw P. Infection with Opisthorchis viverrini and Use of Praziquantel among a Working-age Population in Northeast Thailand. Asian Pac J Cancer Prev 2013;14:2963-6
8. Fleming KA, Boberg KM, Glaumann H, et al. Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2001;34:360-5
9. Lewis JT, Talwalkar JA, Rosen CB, et al. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol 2010;34:27-34
10. Enjoji M, Nakamuta M, Nawata H. Oncogenes in tumors of gallbladder and biliary tract. Fukuoka Igaku Zasshi 2004;95:31-5
11. Klump B, Hsieh CJ, Dette S, et al. Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease. Clin Cancer Res 2003;9:1773-8
12. Morales CP, Burdick JS, Saboorian MH, et al. In situ hybridization for telomerase RNA in routine cytologic brushings for the diagnosis of pancreaticobiliary malignancies. Gastrointest Endosc 1998;48:402-5
13. Saluja SS, Sharma R, Pal S, et al. Differentiation between benign and malignant hilar obstructions using labaratory and radiological investigations: A prospective study. HPB (Oxford) 2007;9:373-82
14. Fernandez- Esparrach G GA, Sanchez M, Page´s M, et al. Comparison of endoscopic ultrasonography and magnetic resonance cholangiopancreatography in the diagnosis of pancreatobiliary diseases: A prospective study. Am J Gastroenterol 2007;102:1632-9
15. Sai JK, Kubokawa SM, Watanabe S, et al. Early detection of extrhepatic bile-duct carcinomas in the nonicteric stage by using MRCP followed by EUS. Gastrointest Endosc 2009;70:29-36
16. de Bellis M, Sherman S, Fofel EL, et al. Tissue sampling at ERCP in suspected malignant biliary strictures (Part 2). Gastrointest Endosc 2002;56:720-30
17. Baron TH, Harewood GC, Rumalla A, et al. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol 2004;2:214-19
18. Harewood GC, Baron TH, Stadheim LM, et al. Prospective, blinded assessment of factors influencing the accuracy of biliary cytology interpretation. Am J Gastroenterol 2004;99:1464-9
19. Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreobiliary strictures. Gasroenterology 2006;131:1064-72
20. Mohamadnejad M, DeWitt JM, Sherman S. Role of EUS for preoperative evaluation of cholangiocarcinoma: A large single-center experience. Gastrointest Endosc 2011;73(1):71-8
21. Tischendorf JJ, Kruger M, Trautwein C, et al. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholanditis. Endoscopy 2006;38:665-9
22. Chen YK, Parsi MA, Binmoeller KF, et al. Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with video). Gastrointest Endosc 2011;74:804-14
23. Hoffman A, Kiesslich R, Bittinger F, et al. Methylene blue-aided cholangioscopy in patients with biliary strictures: Feasibility and outcome analysis. Endoscopy 2008;40:563-71
24. Itoi T, Sofuni A, Itokawa F, et al. Peroral cholangioscopic diagnosis of biliary-tract diseases by using narrow-band imaging (with videos). Gastrointest Endosc 2007;66(4):730-6
25. Lu XL, Itoi T, Kubota K. Cholangioscopy by using narrow-band imaging and transpapillary radiotherapy for mucin-producing bile duct tumour. Clin Gastroenterol Hepatol 2009;7:e34-5
26. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463-73. discussion 473-5
27. Blechacz BR, Sanchez W, Gores GJ. A conceptual proposal for staging ductal cholangiocarcinoma. Curr Opin Gastroenterol 2009;25:238-9
28. Matull WR, Khan SA, Pereira SP. Re: Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2007;99:407; author reply 407-8
29. Anderson CD, Pinson CW, Berlin J, et al. Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004;9:43-57
30. Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet 2005;366:1303-14
31. Reddy SB, Patel T. Current approaches to the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep 2006;8:30-7
32. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81
33. Nehls O, Gregor M, Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004;24:139-54
34. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27
35. Bonney GK, Craven RA, Prasad R, et al. Circulating markers of biliary malignancy: Opportunities in proteomics? Lancet Oncol 2008;9:149-58
36. Kim HJ, Kim MH, Myung SJ, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: Analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999;94:1941-6
37. Ventrucci M, Pozzato P, Cipolla A, et al. Persistent elevation of serum CA 19-9 with no evidence of malignant disease. Dig Liver Dis 2009;41:357-63
38. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: A true increase? J Hepatol 2004;40:472-7
39. Abi-Rached B, Neugut AI. Diagnostic and management issues in gallbladder carcinoma. Oncology (Williston Park) 1995;9:19-24.discussion 24, 27, 30
40. Sinakos E, Saenger AK, Keach J. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol 2011;9:434-9.e1
41. Hotakainen K, Tanner P, Alfthan H. Comparison of three immunoassays for CA 19-9. Clin Chim Acta 2009;400:123-7
42. Koopmann J, Thuluvath PJ, Zahurak ML, et al. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 2004;101:1609-15
43. Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis 2006;6:42-51
44. LaRusso NF, Shneider BL, Black D. Primary sclerosing cholangitis: Summary of a workshop. Hepatology 2006;4:746-64
45. Goydos JS, Brumfield AM, Frezza E, et al. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: Validation of utility as a clinical marker. Ann Surg 1998;227:398-404
46. Cheon YK, Cho YD, Moon JH, et al. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol 2007;102:2164-70
47. Tangkijvanich P, Thong-ngam D, Theamboonlers A, et al. Diagnostic role of serum interleukin 6 and CA 19-9 in patients with cholangiocarcinoma. Hepatogastroenterology 2004;51:15-19
48. Sandanayake NS, Sinclair J, Andreola F, et al. A combination of serum leucine-rich alpha-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Br J Cancer 2011;105:1370-8
49. Bamrungphon W, Prempracha N, Bunchu N, et al. A new mucin antibody/ enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett 2007;247:301-8
50. Wongkham S, Sheehan JK, Boonla C, et al. Serum MUC5AC mucin as a potential marker for cholangiocarcinoma. Cancer Lett 2003;195:93-9
51. Matull WR, Andreola F, Loh A, et al. MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer. Br J Cancer 2008;98:1675-81
52. Boonla C, Wongkham S, Sheehan JK, et al. Prognostic value of serum MUC5AC mucin in patients with cholangiocarcinoma. Cancer 2003;98:1438-43
53. Park SY, Roh SJ, Kim YN, et al. Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: Prognostic impact. Oncol Rep 2009;22:649-57
54. Yi Y, Li B, Wang Z, et al. CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Biomarkers 2009;14:480-5
55. Mizuguchi S, Nishiyama N, Iwata T, et al. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer. Lung Cancer 2007;58:369-75
56. Uenishi T, Yamazaki O, Tanaka H, et al. Serum cytokeratin 19 fragment( CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol 2008;15:583-9
57. Kashihara T, Ohki A, Kobayashi T, et al. Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level. J Gastroenterol 1998;33:447-53
58. Chapman MH, Sandanayake NS, Andreola F, et al. Circulating CYFRA 21-1 is a Specific Diagnostic and Prognostic Biomarker in Biliary Tract Cancer. J Clin Exp Hepatol 2011;1:6-12
59. Lempinen M, Isoniemi H, Makisalo H, et al. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J Hepatol 2007;47:677-83
60. Watanabe H, Enjoji M, Nakashima M, et al. Clinical significance of serum RCAS1 levels detected by monoclonal antibody 22-1-1 in patients with cholangiocellular carcinoma. J Hepatol 2003;39:559-63
61. Enjoji M, Yamaguchi K, Nakamuta M, et al. Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases. Dig Liver Dis 2004;36:622-7
62. Enjoji M, Nakamuta M, Yamaguchi K, et al. RCAS1, a useful serum marker to predict the recurrence of cancer: Two cases of cholangiocarcinoma and pancreatic cancer. Dig Dis Sci 2004;49:1654-6
63. Shi RY, Yang XR, Shen QJ, et al. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery. Cancer 2013;119:993-1003
64. Tolek A, Wongkham C, Proungvitaya S, et al. Serum alpha1beta-glycoprotein and afamin ratio as potential diagnostic and prognostic markers in cholangiocarcinoma. Exp Biol Med( Maywood) 2012;237:1142-9
65. Liu L, Wang J, Liu B, et al. Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma. J Cell Biochem 2008;104:745-55
66. Alvaro D, Macarri G, Mancino MG, et al. Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. Ann Intern Med 2007;147:451-9
67. Li YG, Zhang N. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma. Dig Liver Dis 2009;41:605-8
68. Jamnongkan W, Techasen A, Thanan R, et al. Oxidized alpha-1 antitrypsin as a predictive risk marker of opisthorchiasis-associated cholangiocarcinoma. Tumour Biol 2013;34:695-704
69. Huang Q, Liu L, Lui CH, et al. Expression of Smad7 in cholangiocarcinoma: Prognostic significance and implications for tumor metastasis. Asian Pac J Cancer Prev 2012;13:5161-5
70. Alvaro D, Barbaro B, Franchitto A, et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol 2006;169:877-88
71. Chen CY, Tsai WL, Wu HC, et al. Diagnostic role of biliary pancreatic elastase for cholangiocarcinoma in patients with cholestasis. Clin Chim Acta 2008;390:82-9
72. Ayaru L, Stoeber K, Webster GJ, et al. Diagnosis of pancreaticobiliary malignancy by detection of minichromosome maintenance protein 5 in bile aspirates. Br J Cancer 2008;98:1548-54
73. Chen CY, Lin XZ, Tsao HC, et al. The value of biliary fibronectin for diagnosis of cholangiocarcinoma. Hepatogastroenterology 2003;50(52):924-7
74. Shen J, Wang W, Wu J, et al. Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma. PLoS ONE 2012;7(10):e47476
75. Dhar DK, Olde Damink SW, Brindley JH, et al. Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer. Cancer 2013;119:575-85 Transfection of M2-PK in a negatively expressed cell line (HuCCT-1 cells) increased cell invasion, whereas silencing in an M2-PK-positive cell line (TFK cells) decreased tumor nodule formation and cellular invasion
76. Alpini G, Invernizzi P, Gaudio E, et al. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res 2008;68(22):9184-93
77. Coufal M, Invernizzi P, Gaudio E, et al. Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma. Int J Cancer 2010;126:2112-22
78. Huang L, Frampton G, Rao A, et al. Monoamine oxidase A expression is suppressed in human cholangiocarcinoma via coordinated epigenetic and IL-6-driven events. Lab Invest 2012;92:1451-60
79. Frampton G, Invernizzi P, Bernuzzi F, et al. Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut 2012;61:268-77
80. Metzger J, Negm AA, Plentz RR, et al. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut 2012;62(1):122-30
81. Vasilieva LE, Papadhimitriou SI, Dourakis SP. Modern diagnostic approaches to cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2012;11(4):349-59
82. Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006;131:1064-72
83. Bergquist A, Tribukait B, Glaumann H, et al. Can DNA cytometry be used for evaluation of malignancy and premalignancy in bile duct strictures in primary sclerosing cholangitis? J Hepatol 2000;33:873-7
84. Bangarulingam SY, Bjornsson E, Enders F, et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology 2010;51:174-80
85. Lindberg B, Enochsson L, Tribukait B, et al. Diagnostic and prognostic implications of DNA ploidy and S-phase evaluation in the assessment of malignancy in biliary strictures. Endoscopy 2006;38:561-5
86. American Society for Gastrointestinal Endoscopy (ASGE) Standards of Practice Committee. Anderson MA, Appalaneni V, Ben-Menachem T, et al. The role of endoscopy in the evaluation and treatment of patients with biliary neoplasia. Gastrointest Endosc 2013;77:167-74
87. Ghatnekar O, Andersson R, Svensson M, et al. Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature. Int J Cancer 2013; doi: 10.1002/ijc.28256
88. Briggs CD, Neal CP, Mann CD, et al. Prognostic molecular markers in cholangiocarcinoma: A systematic review. Eur J Cancer 2009;45:33-47
89. Wise C, Pilanthananond M, Perry BF, et al. Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol 2008;14:2986-9
90. Boonjaraspinyo S, Boonmars T, Wu Z, et al. Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma. Tumour Biol 2012;33:1785-802
91. Karamitopoulou E, Tornillo L, Zlobec I, et al. Clinical significance of cell cycleand apoptosis-related markers in biliary tract cancer: A tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas. Am J Clin Pathol 2008;130:780-6
92. Yoshida S, Todoroki T, Ichikawa Y, et al. Mutations of p16Ink4/ CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res 1995;55:2756-60
93. DeHaan RD, Kipp BR, Smyrk TC, et al. An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas. Hum Pathol 2007;38:491-9
94. Uhm KO, Park YN, Lee JY, et al. Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization. Cancer Genet Cytogenet 2005;157:37-41
95. Ryu HS, Chung JH, Lee K, et al. Overexpression of epithelial-mesenchymal transition-related markers according to cell dedifferentiation: Clinical implications as an independent predictor of poor prognosis in cholangiocarcinoma. Hum Pathol 2012;43:2360-70
96. Lee HJ, Chung JY, Hewitt SM, et al. HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma. Virchows Arch 461:521-30
97. Nutthasirikul N, Limpaiboon T, Leelayuwat C, et al. Ratio disruption of the 133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma. Int J Oncol 2013;42:1181-8
98. Koo SH, Ihm CH, Kwon KC, et al. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Genet Cytogenet 2001;130:22-8
99. Shiraishi K, Okita K, Harada T, et al. Comparative genomic hybridization analysis of genetic aberrations associated with development and progression of biliary tract carcinomas. Cancer 2001;91:570-7
100. Andresen K, Boberg KM, Vedeld HM, et al. Novel target genes and a valid biomarker panel identified for cholangiocarcinoma. Epigenetics 2012;7:1249-57
101. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell 2009;136:215-33
102. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat Rev Drug Discov 2010;9:775-89
103. Meng F, Wehbe-Janek H, Henson R, et al. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 2008;27:378-86
104. Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 2010;51:881-90
105. Zhong XY, Yu JH, Zhang WG, et al. MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. Gene 2012;493:44-51
106. Kemper JK. Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications. Biochim Biophys Acta 2011;1812:842-50
107. Teodoro JS, Rolo AP, Palmeira CM. Hepatic FXR: Key regulator of whole-body energy metabolism. Trends Endocrinol Metab 2011;22:458-66
108. Zhang J, Han C, Wu T. MicroRNA-26a promotes cholangiocarcinoma growth by activating beta-catenin. Gastroenterology 2012;143:246-56.e8
109. He Q, Cai L, Shuai L, et al. Ars2 is overexpressed in human cholangiocarcinomas and its depletion increases PTEN and PDCD4 by decreasing microRNA-21. Mol Carcinog 2013;52:286-96
110. Razumilava N, Bronk SF, Smoot RL, et al. miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology 2012;55:465-75
111. Stutes M, Tran S, DeMorrow S. Genetic and epigenetic changes associated with cholangiocarcinoma: From DNA methylation to microRNAs. World J Gastroenterol 2007;13:6465-9
112. Mott JL, Kobayashi S, Bronk SF, et al. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007;26:6133-40
113. Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006;130:2113-29
114. Murugaesu N, Chew SK, Swanton C. Adapting clinical paradigms to the challenges of cancer clonal evolution. Am J Pathol 182:1962-71